BCR and chronic myelogenous leukemia, BCR-ABL1 positive: For example, Shah et al. [8] demonstrate that BCR–ABL inhibitor dasatinib, which has greater potency and a short half-life, can achieve deep clinical remission in CML patients by achieving transient potent BCR–ABL inhibition, while traditionally approved tyrosine kinase inhibitors usually have prolonged half-lives that result in continuous target inhibition.